Neon’s Early Vaccine Study Is a Peek at Immunotherapy’s Third Wave
In this new age of cancer immunotherapy, two versions have been approved. The first are checkpoint inhibitors, which have begun to change the way skin, lung, and other cancers are treated. The second...
View ArticleElanco Boosts Vaccine Portfolio With $60M Prevtec Acquisition
One of the most serious threats to a young farm pig’s life is a type of gut infection that can quickly turn deadly. Elanco Animal Health has acquired a Canadian biotechnology startup that has...
View ArticleMeissa Scores $30M to Test Vaccine for Dangerous Respiratory Virus
No vaccine is yet available for respiratory syncytial virus (RSV), which causes lung infections that, while usually mild, can be deadly for very young children. Biotech startup Meissa Vaccines, which...
View ArticleBiotech Roundup: Vaping Toll Rises, NASH News, Akcea Shakeup & More
Lung injuries linked to electronic cigarettes have topped 800 cases, including 12 deaths, according to the Centers for Disease Control and Prevention. Public health officials aren’t sure whether the...
View ArticleIcosavax Lands $51M to Bring Vaccine for Respiratory Virus to Clinic
Many vaccines are made from either a weakened virus or a protein taken from a virus. But so far, scientists haven’t had much luck developing such vaccines for respiratory syncytial virus (RSV), which...
View ArticleMerck Charts an R&D-Focused Course Starting With a $6.5B Spinoff
Merck is corralling products representing $6.5 billion in sales and spinning them off into a separate company, a strategic bet that focusing the remaining business on developing innovative new...
View ArticleBio Roundup: Clinical Trials Paused, New MS Drug, Kallyope’s Cash & More
Finding and enrolling patients for clinical trials is always challenging. The coronavirus pandemic has made it nearly impossible.Fallout from the spread of COVID-19 infections led several companies to...
View ArticleSanofi Adds mRNA COVID-19 Vaccine Bet Through Translate Bio Alliance
Sanofi is joining the array of companies pursuing a COVID-19 vaccine based on messenger RNA (mRNA), an experimental genetic technology intended to coax the body’s cells into producing proteins that...
View ArticleGSK, Vir Team Up in COVID-19 Pact Aiming to Reach the Clinic in Months
GlaxoSmithKline has agreed to invest $250 million in infectious disease specialist Vir Biotechnology to launch a COVID-19 R&D alliance that the companies say could advance two experimental...
View ArticleInovio Begins Experimental COVID-19 Vaccine Tests in Healthy Volunteers
Inovio Pharmaceuticals, one of the biotechs developing a vaccine to prevent COVID-19, has received the FDA’s OK to start testing its candidate in healthy volunteers.The Plymouth Meeting, PA-based...
View ArticlePfizer, BioNTech Say mRNA COVID-19 Vaccine Trials May Start This Month
Multiple COVID-19 vaccine candidates that use a new technology called messenger RNA are now being readied for clinical trials that Pfizer and BioNTech plan to start in coming weeks.The partnership...
View ArticleGSK and Sanofi Team Up on COVID-19 Vaccine, Aim for Clinic This Year
[Updated, 3:13 p.m. See below.] Pharmaceutical giants GlaxoSmithKline and Sanofi are teaming up on COVID-19 research, aiming to combine their respective technologies in a new vaccine that could start...
View ArticleAffinivax Lands $120M to Take MAPS Tech Into New Vaccine Territory
Affinivax has a lead program with early clinical data showing the potential to best a pharmaceutical giant’s blockbuster vaccine. The startup now has $120 million in financing to see just how much...
View ArticleBio Roundup: Fast FDA Approvals, Biogen Delays, ORIC’s IPO & More
COVID-19’s spread has clamped down on a lot of economic activity, including the work of developing and testing new medicines. But the FDA isn’t showing signs of slowing down, at least when it comes to...
View ArticleBio Roundup: mRNA Vaccine Data, Rise of Rallybio, Roche’s Protein Play & More
As the nation started to reopen this week following two months of closed businesses and stay-at-home orders, public health officials and economists cautioned that society won’t truly return to anything...
View ArticleFauci Foresees “More Than 1 Winner” in Race for COVID-19 Vaccines, Drugs
To ameliorate a pandemic that infectious disease expert Anthony Fauci calls his “worst nightmare,” a winner-takes-all solution won’t be enough.Fauci, who directs the National Institute of Allergy and...
View ArticleModerna Finalizes Plan, Dose for Phase 3 Test of mRNA COVID Vaccine
Less than a month after reporting preliminary early-stage data for its experimental vaccine for the novel coronavirus, Moderna has finalized the plan for a Phase 3 test.The study, set to begin next...
View ArticleBio Roundup: A Royal IPO, Akili Arrives, Orca Bio Surfaces & More
The biggest life sciences deal this week involves a company that doesn’t discover or develop drugs, or even sell them. Yet its mark is found on pharmaceutical products spanning the entire...
View ArticlePfizer, BioNTech Choose Full Spike Protein for Pivotal Vaccine Test
Pfizer and BioNTech’s COVID-19 vaccine research started with multiple approaches—four shots on the messenger RNA goal. The partners have narrowed their choices to one for pivotal testing, and that...
View ArticlePfizer’s Bourla: There’s Coronavirus Vaccine Pressure, But It’s Not Political
Pfizer Inc. CEO Albert Bourla said he doesn’t worry about political pressure to bring potentially the first coronavirus vaccine to market, but can’t escape feeling the weight of the world on his...
View Article
More Pages to Explore .....